Smooth Muscle-Selective Inhibition of Nuclear Factor-kB Attenuates Smooth Muscle Phenotypic Switching and Neointima Formation Following Vascular Injury

Journal of the American Heart Association

Volumn 2, Issue 3, 2013, Pages

  Yoshida, Tadashi ^a   Yamashita, Maho ^a   Horimai, Chihiro ^a   Hayashi, Matsuhiko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Klf4; Myocardin; Nuclear factor kB; Smooth muscle cells

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ALPHA SMOOTH MUSCLE ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYOCARDIN; TRANSGELIN; I KAPPA B; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAROTID ARTERY INJURY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE SWITCHING; IMMUNOPRECIPITATION; IN VIVO STUDY; MALE; MOUSE; MYOCARDIN GENE; NEOINTIMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RAT; SM ALPHA ACTIN GENE; SM22ALPHA GENE; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION; ANIMAL; BLOOD VESSEL INJURY; GENETICS; NUCLEAR FACTOR-ΚB; PHYSIOLOGY; REGULATOR GENE; SMOOTH MUSCLE CELLS; TRANSGENIC MOUSE; COMPLICATION;

KLF4; MYOCARDIN; NUCLEAR FACTOR-ΚB; SMOOTH MUSCLE CELLS;

ANIMALS; GENES, SWITCH; I-KAPPA B PROTEINS; MICE; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; NF-KAPPA B; NUCLEAR PROTEINS; PHENOTYPE; TRANS-ACTIVATORS; VASCULAR SYSTEM INJURIES;

EID: 84889812425     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.113.000230     Document Type: Article

References (40)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor jB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25:904-914.
3. Landey DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-jB and IjB system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 1997;151:1085-1095.
4. Cercek B, Yamashita M, Dimayuga P, Zhu J, Fishbein MC, Kaul S, Shah PK, Nilsson J, Regnstrom J. Nuclear factor-jB activity and arterial response to balloon injury. Atherosclerosis. 1997;131:59-66.
5. Lindner V. The NF-jB and IjB system in injured arteries. Pathobiology. 1998;66:311-320.
6. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996; 97:1715-1722.
7. Bourcier T, Sukhova G, Libby P. The nuclear factor j-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 1997;272:15817-15824.
8. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E. Antisense oligonucleotides to the p65 subunit of NF-jB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun. 1995;213:827-836.
9. Zuckerbraun BS, McCloskey CA, Mahidhara RS, Kim PK, Taylor BS, Tzeng E. Overexpression of mutated IjBa inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J Vasc Surg. 2003;38:812-819.
10. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kB binding site as a novel molecular strategy. Gene Ther. 2001;8:1635-1642.
11. Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H, Makino H, Kaneda Y, Ogihara T, Morishita R. Inhibition of NFjB activation using ciselement 'decoy' of NFjB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther. 2003;10:356-364.
12. Ohtani K, Egashira K, Nakano K, Zhao G, Funakoshi K, Ihara Y, Kimura S, Tominaga R, Morishita R, Sunagawa K. Stent-based local delivery of nuclear factor-jB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation. 2006;114:2773-2779.
13. Grassia G, Maddaluno M, Musilli C, De Stefano D, Carnuccio R, Di Lauro MV, Parratt CA, Kennedy S, Di Meglio P, Ianaro A, Maffia P, Parenti A, Ialenti A. The IjB kinase inhibitor nuclear factor-jB essential modulator-binding domain peptide for inhibition of injury-induced neointimal formation. Arterioscler Thromb Vasc Biol. 2010;30:2458-2466.
14. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M. Endothelial cell-specific NFjB inhibition protects mice from atherosclerosis. Cell Metab. 2008;8:372-383.
15. Kanters E, Gijbels MJ, van der Made I, Vergouwe MN, Heeringa P, Kraal G, Hofker MH, de Winther MP. Hematopoietic NF-jB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood. 2004;103: 934-940.
16. Goossens P, Vergouwe MN, Gijbels MJ, Curfs DM, van Woezik JH, Hoeksema MA, Xanthoulea S, Leenen PJ, Rupec RA, Hofker MH, de Winther MP. Myeloid IjBa deficiency promotes atherogenesis by enhancing leukocyte recruitment to the plaques. PLoS ONE. 2011;6:e22327.
17. Gomez D, Owens GK. Smooth muscle phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95:156-164.
18. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003;35:577-593.
19. Yoshida T, Owens GK. Molecular determinants of vascular smooth muscle cell diversity. Circ Res. 2005;96:280-291.
20. Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, Olson EN. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature. 2004;428:185-189.
21. Zhou J, Hu G, Herring BP. Smooth muscle-specific genes are differentially sensitive to inhibition by Elk-1. Mol Cell Biol. 2005;25:9874-9885.
22. Yoshida T, Gan Q, Shang Y, Owens GK. Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters. Am J Physiol Cell Physiol. 2007;292:C886-C895.
23. Adam PJ, Regan CP, Hautmann MB, Owens GK. Positive-and negative-acting Kr€uppel-like transcription factors bind a transforming growth factor b control element required for expression of the smooth muscle cell differentiation marker SM22α in vivo. J Biol Chem. 2000;275:37798-37806.
24. Liu Y, Sinha S, McDonald OG, Shang Y, Hoofnagle MH, Owens GK. Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J Biol Chem. 2005;280:9719-9727.
25. Yoshida T, Gan Q, Owens GK. Kr€uppel-like factor 4, Elk-1, and histone deacetylases cooperatively suppress smooth muscle cell differentiation markers in response to oxidized phospholipids. Am J Physiol Cell Physiol. 2008;295:C1175-C1182.
26. Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA, Thomas JA, Leitinger N, Owens GK. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res. 2007;101:792-801.
27. Yoshida T, Kaestner KH, Owens GK. Conditional deletion of Kr€uppel-like factor 4 delays downregulation of smooth muscle cell differentiation markers but accelerates neointimal formation following vascular injury. Circ Res. 2008;102:1548-1557.
28. Zhang J, Zhong W, Cui T, Yang M, Hu X, Xu K, Xie C, Xue C, Gibbons GH, Liu C, Li L, Chen YE. Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol. 2006;26: e23-e24.
29. Inoue T, Takenaka T, Hayashi M, Monkawa T, Yoshino J, Shimoda K, Neilson EG, Suzuki H, Okada H. Fibroblast expression of an IjB dominant-negative transgene attenuates renal fibrosis. J Am Soc Nephrol. 2010;21:2047-2052.
30. Yoshida T, Gan Q, Franke AS, Ho R, Zhang J, Chen YE, Hayashi M, Majesky MW, Somlyo AV, Owens GK. Smooth and cardiac muscle-selective knock-out of Kr€uppel-like factor 4 causes postnatal death and growth retardation. J Biol Chem. 2010;285:21175-21184.
31. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792-796.
32. Yoshida T, Sinha S, Dandré F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res. 2003;92:856-864.
33. Shang Y, Yoshida T, Amendt BA, Martin JF, Owens GK. Pitx2 is functionally important in the early stages of vascular smooth muscle cell differentiation. J Cell Biol. 2008;181:461-473.
34. Yoshida T, Yamashita M, Hayashi M. Kr€uppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. J Biol Chem. 2012;287:25706-25714.
35. Creemers EE, Sutherland LB, McAnally J, Richardson JA, Olson EN. Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development. 2006;133:4245-4256.
36. Alexander MR, Murgai M, Moehle CW, Owens GK. Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-jB-dependent mechanisms. Physiol Genomics. 2012;44:417-429.
37. Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, Banerjee A. Liposomal delivery of purified inhibitory-jBa inhibits tumor necrosis factor-a-induced human vascular smooth muscle proliferation. Circ Res. 1999;84:867-875.
38. Wassmann S, Wassmann K, Jung A, Velten M, Knuefermann P, Petoumenos V, Becher U, Werner C, Mueller C, Nickenig G. Induction of p53 by GKLF is essential for inhibition of proliferation of vascular smooth muscle cells. J Mol Cell Caridol. 2007;43:301-307.
39. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-jB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest. 1995;96:2521-2527.
40. Tang R, Zheng XL, Callis TE, Stansfield WE, He J, Baldwin AS, Wang DZ, Selzman CH. Myocardin inhibits cellular proliferation by inhibiting NF-jB(p65)-dependent cell cycle progression. Proc Natl Acad Sci USA. 2008;105:3362-3367.